

Title

Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the hypertensive, obese, type 2 diabetic SDT fatty rat model of diabetic kidney disease

Yuichi Shinozaki¹, Yuko Katayama², Fuminari Yamaguchi², Tomohisa Suzuki², Kana Watanabe³, Kinuko Uno³, Takahiro Tsutsui¹, Miki Sugimoto¹, Masami Shinohara⁴, Katsuhiro Miyajima³ and Takeshi Ohta¹

¹*Laboratory of Animal Physiology and Functional Anatomy, Graduate School of Agriculture, Kyoto University, Kyoto, Japan*

²*Research Division, SCOHIA PHARMA, Inc., Kanagawa, Japan*

³*Department of Nutritional Science and Food Safety, Faculty of Applied Biosciences, Tokyo University of Agriculture, Tokyo, Japan*

⁴*CLEA Japan Inc., Tokyo, Japan*

Short title

Salt loading with unilateral nephrectomy accelerates decline in glomerular filtration rate in the SDT fatty rat model of diabetic kidney disease

Author for correspondence

Yuichi Shinozaki

Address: Laboratory of Animal Physiology and Functional Anatomy, Graduate School of
Agriculture, Kyoto University, Kyoto 606-8502, Japan

Tel.: + 81-75-753-6325

E-mail: shinozaki.yuichi.64s@st.kyoto-u.ac.jp

Abstract

For the evaluation of novel therapeutic agents for diabetic kidney disease (DKD), it is desirable to examine their efficacy in animal models by using the glomerular filtration rate (GFR) as an index. For this purpose, animal models that demonstrate a short-term GFR decline due to disease progression are required. Therefore, we aimed to develop such an animal model of DKD by using obese type 2 diabetic Spontaneously Diabetic Torii (SDT) fatty rats treated with salt loading by drinking water containing sodium chloride with or without unilateral nephrectomy. As a result, we have found that 0.3% salt loading with unilateral nephrectomy or 0.8% salt loading alone caused a rapid GFR decline, hypertension and rapid development of tubulointerstitial fibrosis. Moreover, the addition of losartan to a mixed diet suppressed the GFR decline in SDT fatty rats treated with 0.3% salt loading with unilateral nephrectomy. These results suggest that the model of SDT fatty rats treated with 0.3% salt loading and unilateral nephrectomy could be used as a hypertensive DKD model for evaluating therapeutic agents based on suppression of GFR decline.

Keywords: SDT fatty rat, salt loading, unilateral nephrectomy, GFR decline,

1. Introduction

Diabetic kidney disease (DKD) is characterized by a complicated pathology that involves

hyperglycemia, hyperlipidemia, obesity, and hypertension, accompanied by a decline in glomerular filtration rate (GFR). The estimated GFR (eGFR) is frequently used to assess renal function in patients with DKD. That is, an eGFR decline indicates a decrease in renal function. For more than a decade, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) such as ramipril or losartan have been used for the treatment of diabetic nephropathy¹. However, the target populations of these agents are limited to patients suffering from diabetic nephropathy with type 2 diabetes, hypertension, elevated plasma creatinine, and proteinuria^{2,3}. In recent years, evidence of the efficacy of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with DKD has been accumulating⁴, and it is likely that the treatment strategy will be changed in the near future so that SGLT2 inhibitors can become the basic medication used for DKD patients⁵.

Various animal models of DKD are known, however, the complex etiological complications associated with decreased renal function in patients with DKD, develop in only a few of them. As an example, the widely used streptozotocin (STZ)-induced type 1 diabetes model, unlike humans, shows elevated blood glucose levels but not hyperlipidemia or hypertension. Whereas, endothelial nitric oxide synthase (eNOS) (-/-) db/db mice, SHR/NDmcr-cp (cp/cp) rats, and Zucker diabetic fatty rats, which are hypertensive DKD models with such complications, must be more than 6 months old before nephropathy develops with histopathological changes⁶⁻¹². Furthermore, these animal models do not exhibit a GFR decline

during this period, but rather they show an increase in GFR due to glomerular hyperfiltration¹³. Therefore, there are currently no pharmacologically available animal models of DKD that show a GFR decline, which is a surrogate for renal function in patients with DKD.

The SDT fatty rat is an obese, type 2 diabetic model of DKD characterized by hyperglycemia, hyperlipidemia, and hypertension¹⁴⁻¹⁸. By utilizing SDT fatty rats, we attempted to establish an accelerated hypertensive DKD model in which GFR decline, and these characteristics develop rapidly. To accelerate the decrease in renal function, salt loading with or without unilateral nephrectomy was performed, and in addition, the efficacy of ARBs (losartan, in particular) was evaluated.

2. Results

2.1 Effect of salt loading with or without unilateral nephrectomy (UNx) on renal function

A significant increase in GFR was observed in untreated SDT fatty rats (SDT fatty rats provided with normal drinking water) compared to Sprague Dawley (SD) rats, and the increase persisted throughout the experiment. On the other hand, a significant decrease in GFR was observed in the rats undergoing 0.6% salt loading without UNx (0.6% salt), 0.8% salt loading without UNx (0.8% salt), or 0.3% salt loading with UNx (0.3% salt/UNx),

compared to the untreated SDT fatty rats. Furthermore, the GFR was significantly lower in the rats with 0.3% salt/UNx at week 13 than in SD rats. In addition, elevated urinary albumin-creatinine ratio (UACR) was observed in the untreated SDT fatty rats, and was further increased by 0.3% salt/UNx, 0.6% salt, or 0.8% salt (Fig. 1).

2.2 Effect on renal related and metabolic parameters

During the experimental period, higher plasma creatinine (pCre) and blood urea nitrogen (BUN) levels were observed in rats treated with 0.3% salt/UNx compared to other treated SDT fatty rats; chronic hyperglycemia was observed in untreated SDT fatty rats compared to SD rats, however, lower plasma glucose levels were observed in rats treated with 0.3% salt/UNx, 0.6% salt, or 0.8% salt, and were accompanied by a decrease in hemoglobin A1c levels at week 12. Plasma total cholesterol and triglyceride levels, which are elevated in SDT fatty rats, were increased by salt loading (Fig. 2).

2.3 Effect on renal histology

Histopathologically, tubulointerstitial fibrosis was prominently observed in the untreated SDT fatty rats at week 13. Moreover, treatment with 0.8% salt and 0.3% salt/UNx resulted in increased interstitial fibrosis. Glomerular hypertrophy, mesangial hyperplasia, and interstitial infiltration of inflammatory cells were induced by treatment with 0.6% salt, 0.8% salt, and

0.3% salt/UNx (Fig. 3). A significant increase in glomerular size was observed in untreated SDT fatty rats compared to SD rats. Furthermore, SDT fatty rats treated with 0.8% salt had significantly larger glomerular size than untreated SDT fatty rats. The average size (μm^2) of glomeruli in the SD rats, untreated SDT fatty rats, 0.6% salt treated rats, 0.8% salt treated rats, and 0.3% salt/UNx treated rats were (7594 ± 484 , 12427 ± 1365 , 14746 ± 1695 , 16030 ± 4192 , and 15401 ± 1359), respectively. Disruption of the glomerulus was observed in rats treated with 0.8% salt (data not shown).

2.4 Effect of losartan on GFR decline and renal histology in rats treated with 0.3% salt loading and UNx

Next, we investigated the effect of losartan on GFR decline in rats treated with 0.3% salt/UNx. The results showed that dietary administration of losartan (10 mg/kg/day) significantly suppressed GFR decline in the rats treated with 0.3% salt/UNx (Fig. 4). Histopathologically, it was found that 0.3% salt/UNx caused glomerular lesions (hypertrophy, adhesion, increase in mesangial matrix), tubular lesions (cast formation, regeneration, expansion) and tubulointerstitial lesions (fibrosis, inflammatory cell infiltration). However, no improvement was evident with administration of losartan, and in several cases, limited improvement in tubular dilatation and cast formation was detected (data not shown).

3. Discussion

In SDT fatty rats, 0.3% salt loading by drinking water with unilateral nephrectomy (0.3% salt/UNx), or 0.8% salt loading alone, was able to induce an early decline in GFR as well as an elevated UACR, accompanied by histopathological changes such as kidney fibrosis, glomerular hypertrophy, and inflammatory cell infiltration (Fig. 1A-C, Fig. 3). Furthermore, 0.3% salt/UNx caused renal-related parameters such as pCre and BUN to increase, in contrast to 0.8% salt loading alone (Fig. 2A, 2B). The hallmarks of DKD include GFR decline, albuminuria, and impaired renal morphology (increased glomerular basement membrane thickness, mesangial hyperplasia, interstitial fibrosis, glomerular hypertrophy, glomerulosclerosis, podocyte foot process effacement, and arterial hyalinosis)¹⁹. The induction of decreased renal function by 0.3% salt/UNx in SDT fatty rats was suggested to be reminiscent of the pathological condition in patients with hypertensive DKD, as indicated above.

Recently, induced renal injury by dietary salt loading in the Dahl salt-sensitive hypertensive rat has been used as an animal model to evaluate the efficacy of agents for antihypertensive treatment^{20,21}. Although the Dahl salt-sensitive hypertensive rat is a model of hypertension, it is not a model to study risk factors specific to DKD, such as diabetes mellitus, abnormal lipid metabolism, and obesity. SHR/NDmcr-cp (cp/cp) rats and db/db mice, which are known diabetic models, show signs of DKD, such as abnormal lipid metabolism and obesity,

however, during the lifetime of the animals, renal function is not influenced or in a hyperfiltration state, and infrequently declines as measured by creatinine clearance^{7,22,23}. Therefore, the SDT fatty rat treated with salt loading alone exhibits a more rapid GFR decline and this model might mimic the pathogenesis of DKD in patients.

On the other hand, salt loading might not cause hyperfiltration since it would not induce contraction of the efferent arteriole by inhibiting the activation of renin-angiotensin system in the renal glomerulus²⁴. This could lead to a more rapid and direct detection of the effects of various risk factors on renal function. However, since salt loading is likely to cause an increase in body fluid volume, renal-related parameters in the blood, such as pCre and BUN, may not be elevated even though these parameters usually increase with a decrease in renal function. Therefore, it is preferable to influence renal function by using a lower salt concentration for loading.

To further accelerate the decline of renal function, we performed unilateral nephrectomy (UNx) in addition to salt loading. By promoting renal dysfunction via reducing the number of nephrons, UNx and 5/6 nephrectomy in rats and mice are widely used as experimental models of chronic kidney disease (CKD)²⁵⁻²⁷.

In the present study, we performed UNx as well as 0.3% salt loading in rats, which allowed

us to establish a model in which even loading a low concentration of salt would lead to steady GFR decline, hypertension and worsened renal function parameters, accompanied by renal histopathological changes. It was considered that the decrease in the number of nephrons due to nephrectomy causes an increase in the single nephron GFR, and the sustained hypertension due to salt loading accelerates glomerulosclerosis and intensifies medullary hypoxia, resulting in further reduction in the number of nephrons and hypoxia caused by interstitial fibrosis²⁸⁻³⁰. Furthermore, in this study, plasma total cholesterol (TC) and triglyceride (TG) levels were elevated in rats treated with 0.3% salt/UNx as well as 0.6% salt loading alone or 0.8% salt loading alone (data not shown). In a healthy condition, both TG and TC are known to be absorbed by the renal cells such as tubular epithelial cells and used as energy source or lipid membrane components. However, in CKD condition, the intracellular factors involved in their utilization are decreased, and these could accumulate as lipid droplets and exert cytotoxic effects^{31,32}. It has also been reported that triglycerides and free fatty acids (FFAs) bound to albumin accumulated in the proximal tubules could cause damage and induce inflammation³¹. Furthermore, our model is characterized by hypertension. In the preliminary study, systolic blood pressure levels (mmHg) of SD rats and 0.3% salt/UNx treated rats were 105.3 ± 23.8 and 209.6 ± 24.2 after 5 weeks of treatment, and 126.8 ± 12.5 and 191.4 ± 35.4 after 10 weeks of treatment, respectively, measured by the indirect tail cuff method²⁵.

Unfortunately, it was not possible to identify the lesion as a prominent change due to the

depth of the renal area observed. In addition, because the changes appeared in each nephron, we considered it difficult to observe pathological shift from a cortical layer to a deeper layer. Additionally, decrease in blood glucose levels were observed in these rats (Fig. 2C). The reason for the decrease in the levels might be related to the downward trend in food intake of SDF Fatty rats treated with salt loading³³. On the other hand, there is also a possibility that sodium loading might impair the function of SGLT1 in the intestine, however, these should be the themes for our future study.

Next, we confirmed the effect of losartan, which is widely used for the treatment of diabetic nephropathy⁴. The results showed that dietary administration of losartan attenuated the GFR decline induced by 0.3% salt loading and UNx in rats (Fig. 4). However, the results of histopathological evaluation showed that the efficacy of losartan was partial. The average size (μm^2) of glomeruli was comparable to the normal diet, showing no efficacy (normal diet : 14475 ± 3016 , losartan diet : 17173 ± 3539). Previous reports suggest that it could be that the ARBs acted as neuroprotective agents to prevent GFR decline as another function of losartan other than reducing efferent artery constriction^{34,35}. These results suggest that this model might mimic the later stages of DKD, where ACE inhibitors and ARBs are less effective in clinical care. Whereas, the GFR of SD rats appeared spontaneously decreased in Fig.4, it was considered that there was a possibility of detecting the aging-related decrease to some degree³⁶.

In preclinical studies, the lack of animal models that mimic the pathophysiological characteristics of patients with DKD has been an obstacle to address the clinical needs precisely³⁷. Animal models might provide new-insights into the development and progression of nephropathy in patients with DKD, and help us better understand the etiology of the disease. In addition, animal models could be used to explain how novel therapies might function, identify alternative pathways for these therapies, and even help to validate the onset of potential side effects.

In patients with DKD, risk factors such as hypertension, dyslipidemia, and hyperuricemia, in addition to diabetes mellitus, are considered to be complex pathological determinants. Thus, we considered that our model is also characterized by including these risk factors in addition to diabetes. On the other hand, it is unknown which of these factors, including hypertension, contributes to the pathogenesis of the patients. In this study, plasma TG and TC levels were elevated in our hypertensive DKD model (data not shown). The dyslipidemia in CKD patients is characterized by elevated TG and TC, therefore, in our model, we intended to mention these elevations. For the mechanism of TG and TC elevation in our model, the article by M Lee et al. that studied the response of Adipocytes to salt loading³⁸ might be informative. This study reported that high salt increased the expression of adipogenic/lipogenic genes and, inversely, decreased the gene of lipolysis.

In the past, ACE inhibitors and ARBs, two groups of anti-hypertensive medications that slow the progression of diabetic nephropathy (DN), have been extensively studied in various experimental DN models. However, not all the typical DN features develop in many of these models. For example, the mouse model has several limitations, and only the early stages of diabetic kidney disease develop in this model. In fact, the classical model of DN only exhibits the features of early stage DKD: moderate albuminuria, glomerular hypertrophy, and slight expansion of the mesangial matrix³⁹. Glomerulosclerosis, tubular atrophy, or interstitial fibrosis is rarely presented in these animals. The model presented herein, which is produced by the combination of UNx and salt loading, is a novel animal model that exhibits many of the features observed in patients with DKD and therefore might be helpful in characterizing the mechanisms involved in this disease. Recently, it was reported that, in hypertensive DKD mouse model, under conditions in which spironolactone and esaxerenone showed similar reduction in blood pressure, esaxerenone elicited a greater attenuation of albuminuria, glomerular injury, tubulointerstitial fibrosis, and renal inflammation than spironolactone⁴⁰.

In the future, we expect to use our model to evaluate the effects of DPP-IV inhibitor/SGLT2 inhibitor alone or in combination with ACE inhibitors or ARBs and to understand the characteristics and limitations of this model by comparing this model to patients with DKD, which will allow us to further characterize the pathogenic factors other than hypertension in our model. It was reported that ARB reduced proteinuria even though it was not effective for

blood pressure⁴¹. In addition, ARBs are neuroprotective agents, therefore, it is possible that ARBs have a renoprotective effect through this action³⁵. As mentioned above, we would like to establish the position of our model by evaluating the efficacy of agents with other mechanisms of action other than the antihypertensive effect of ARBs on our model in the future.

4. Materials and Methods

4.1 Animals

Male SDT fa/fa (fatty) rats and age-matched Sprague-Dawley (SD) rats were purchased from CLEA Japan, Inc. (Tokyo, Japan), and maintained in a specific pathogen-free room at a temperature of $23 \pm 3^\circ\text{C}$ and air humidity of $55 \pm 15\%$, on a 12-h/12-h light/dark cycle. This animal study was conducted in accordance with the Japanese Law for the Humane Treatment and Management of Animals (Law No. 105, October 1, 1973).

4.2 Chemicals

Losartan ($\geq 98\%$ purity) was purchased from LKT Laboratories, Inc. (St. Paul, Minnesota, USA). The losartan diet was prepared every week by mixing losartan with standard powdered chow (CE-2, CLEA Japan Inc.), adjusting the mixture ratio based on the body weight and

average dietary intake of the rats. The mixed diet containing approximately 0.015% losartan (10 mg/kg/day) was fed for 10 weeks.

4.3 Effects of salt loading with or without unilateral nephrectomy (UNx) on glomerular filtration rate (GFR)

The study design is shown in Figure 5A. Animals at 9 weeks old were divided into 5 treatment groups based on the measurements of GFR: 1) SDT fatty rats drinking normal water and not nephrectomized (without UNx), 2) SDT fatty rats salt loaded by drinking 0.3% salt water and nephrectomized (with UNx), 3) SDT fatty rats salt loaded by drinking 0.6% salt water without UNx, 4) SDT fatty rats salt loaded by drinking 0.8% salt water without UNx, or 5) SD rats not salt loaded by drinking normal water without UNx. Unilateral nephrectomy (left kidney) for the rats in the 0.3% salt loaded group was performed as previously described²⁵. In order to establish a model with a decrease in GFR, the salt concentration used for salt loading was investigated. Our previous study showed that 0.3% salt loading alone nor UNx treatment alone did not decrease creatinine clearance¹⁶, so the combination of the 0.3% salt water with UNx group was set up. In the following week, these groups started to the salt-loading treatment by drinking water containing 0, 0.3, 0.6, or 0.8% salt for 13 weeks. During the experimental period, body weight was measured sequentially, and blood and urine samples were collected from the tail vein and using metabolic cages,

respectively. As a parameter of renal function, GFR was measured before group assignment and at 2, 6, 10, and 13 weeks after salt loading. GFR was determined by measuring the plasma clearance of fluorescein isothiocyanate (FITC)-labeled inulin after a single bolus injection as previously described⁴². After the last sampling at week 13, the rats were euthanized and their right kidneys were excised and processed for histological evaluation. Plasma glucose, pCre, BUN, and urine creatinine levels were measured using an automatic biochemical analyzer (Model 7180, Hitachi High-Technologies Corporation, Tokyo, Japan). Plasma insulin levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Morinaga Institute of Biological Science, Inc., Kanagawa, Japan). Urine albumin levels were measured using a commercially available ELISA kit (Shibayagi Co., Ltd., Gunma, Japan). For histological analysis, the 10% neutral formalin-fixed right kidneys were sectioned and stained with hematoxylin and eosin (HE), periodic acid-Schiff (PAS), and Sirius red. PAS staining was used to evaluate the degree of glomerular alteration; HE staining and PAS staining were used to evaluate the degree of tubulointerstitial alteration, and Sirius red staining was used to evaluate the degree of interstitial fibrosis. The histological evaluation was assessed by the following four parameters defined in the preliminary examination: interstitial fibrosis, glomerular hypertrophy, mesangial hyperplasia, and interstitial infiltration of inflammatory cells. Preliminary observation of the entire cortical to medullary regions was performed by using renal

specimens and 4 parameters described above that showed prominent changes were examined in this study. The severity of each histological change was scored on a 5-point scale ranging from 0 to 4 (Score 0: within normal limits; Score 1: minimal, solitary [very small] lesion; Score 2: slight, focal [small] lesion; Score 3: moderate, scattered lesion; and Score 4: severe, marked, extensive lesion) based on the severity and extent of the change. For evaluation of glomerular change, glomerular sizes in the cortical area were analyzed. To measure glomerular size, one section per rat was photographed under a light microscope (BX51, Olympus Corporation, Tokyo, Japan) using the 4× objective lens and analyzed using ImageJ software (Rasband WS, ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, <https://imagej.nih.gov/ij/>, 1997-2018) as previously described⁴³. Six animals per group were used for measurement of glomerular size. The glomerular area measurement was performed by randomly divided into sections of the entire kidney from the cortical surface to the juxtamedullar, and all glomeruli within the area and overlapping the upper and right edges were counted. Approximately 50 to 100 glomeruli were counted per animal.

4.4 Effects of losartan on GFR decline in SDT fatty rats undergoing 0.3% salt loading with unilateral nephrectomy (UNx)

The study design is shown in Figure 5B. SDT fatty rats were salt-loaded by drinking 0.3% salt water and subjected to UNx based on the results of the study showing the fastest GFR

decline (Fig. 1A).

UNx was done in the SDT fatty rats at 9 weeks old. In the following week, group assignment was performed based on the GFR, and then 0.3% salt loading was started in all rats except SD rats (control group). The groups were: 1) SDT fatty rats fed a normal diet, salt-loaded by drinking 0.3% salt water, and nephrectomized (with UNx); 2) SDT fatty rats fed the 10 mg/kg losartan diet, salt-loaded by drinking 0.3% salt water, and with UNx; 3) SD rats drinking normal water and not nephrectomized (without UNx). Furthermore, a standard powder chow or mixed diet containing losartan (10 mg/kg/day, approximately 0.015%) was fed for 10 weeks. GFR was measured before and at 2, 5, and 10 weeks after salt loading by intravenous injection of FITC-sinistrin as previously described⁴⁴. After the last measurement of GFR, the rats were euthanized, and their right kidneys were excised and processed for histological evaluation as described above.

4.5 Statistical analysis

Data are expressed as the mean and standard deviation (S.D.) of the indicated numbers of animals or samples. All statistical analyses were performed using Statlight 2000 (Yukms Co., Ltd, Kanagawa, Japan). In a two-group comparison, the statistical significance was assessed using Student's t-test (for homoscedastic data) or Aspin-Welch's t-test (for heteroscedastic data) after homoscedasticity analysis by an F-test. In a multi-group comparison, the statistical

significance was assessed using Dunnett's test (for homoscedastic data) or Steel's test (for heteroscedastic data) after homoscedasticity analysis by Bartlett's test. For histological scores, the statistical significance was assessed by Wilcoxon rank sum test for two-group comparison and Steel's test for a multi-group comparison. All statistical analyses were two-sided, and statistically significant level was set at $p < 0.05$.

Disclosure

The authors declare that there are no conflicts of interest regarding this article.

Acknowledgments

We would like to thank ASCA Corporation (<https://www.asca-co.com/>) for the editorial assistance. This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Figure Legends

Figure 1. Effects of salt loading with or without UNx on GFR and urinary albumin level.

A: GFR changes during the experiment period. B: GFR at week 13. C: UACR at week 13

Data points and bars represent the mean and S.D. (n = 6).

$P < 0.01$ vs. SD-water group (Student's *t*-test)

** $P < 0.01$ vs. SDTF-water group (Dunnett's test)

^b $P < 0.05$ vs. SD-water group (Steel's test)

‡ $P < 0.01$ vs. SD-water group (Welch's test)

§ $P < 0.05$ vs. SDTF-water group (Steel's test)

UNx, unilateral nephrectomy; GFR, glomerular filtration rate; UACR, urinary albumin-creatinine ratio; SDTF, SDT Fatty

Figure 2. Effect on renal-related and metabolic parameters

A: Plasma creatinine (pCre). B: Blood urea nitrogen (BUN). C: Plasma glucose. D: HbA1c at week 12. E: Plasma triglyceride. F: Plasma total cholesterol. G: Body weight.

Data points and bars represent the mean and S.D. (n = 6).

$P < 0.01$ vs. SD-water group (Student's *t*-test)

†, ‡ $P < 0.05, P < 0.01$ vs. SD-water group (Welch's test)

** $P < 0.01$ vs. SDTF-water group (Dunnett's test)

§ $P < 0.05$ vs. SDTF-water group (Steel's test)

SDTF, SDT Fatty

Figure 3. Effects of salt loading with or without UNx on renal histopathology.

A: Representative images of Sirius red staining.

B: Interstitial fibrosis. C: Glomerular hypertrophy. D: Mesangial hyperplasia. E: Interstitial infiltration of inflammatory cells

Data points and bars represent the mean and S.D. (n = 6).

$P < 0.01$ vs. SD-water group (Student's *t*-test)

*, ** $P < 0.05$, $P < 0.01$ vs. SDTF-water group (Dunnett's test)

\$\$, $P < 0.01$ vs. SD-water group (Wilcoxon rank sum test)

§, §§ $P < 0.05$, $P < 0.01$ vs. SDTF-water group (Steel's test)

UNx, unilateral nephrectomy; SDTF, SDT Fatty

Figure 4. Effect of losartan diet on GFR decline in rats salt-loaded with 0.3% salt water and subjected to UNx.

Data points and bars represent the mean and S.D. (n = 6).

+ $P < 0.05$ vs. SDTF-0.3% salt/UNx group (Dunnett's test)

GFR, glomerular filtration rate; UNx, unilateral nephrectomy; SDTF, SDT Fatty

Figure 5. Experimental design.

A. Effect of salt loading with or without unilateral nephrectomy (UNx) on renal function

B. Effects of losartan on GFR decline

References

1. Kota SK, Meher LK, Jammula S, Kota SK, Modi KD. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate. *Diabetes Metab Syndr*. 2012;6(4):215-217.
2. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. *Kidney Int*. 2003;63(4):1499-1507.
3. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med*. 2001;345(12):870-878.
4. Tuttle KR, Cherney DZ, Diabetic Kidney Disease Task Force of the American Society of N. Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease. *Clin J Am Soc Nephrol*. 2020;15(2):285-288.
5. Tuttle KR, Brosius FC, 3rd, Cavender MA, et al. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. *Am J Kidney Dis*. 2021;77(1):94-109.
6. Chander PN, Gealekman O, Brodsky SV, et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. *J Am Soc Nephrol*. 2004;15(9):2391-2403.
7. Nangaku M, Izuhara Y, Usuda N, et al. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. *Nephrol Dial Transplant*. 2005;20(12):2661-2669.
8. Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. *J Am Soc Nephrol*. 2006;17(10):2664-2669.
9. Mohan S, Reddick RL, Musi N, et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. *Lab Invest*. 2008;88(5):515-528.
10. Giani JF, Burghi V, Veiras LC, et al. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. *Am J Physiol Renal Physiol*. 2012;302(12):F1606-1615.
11. Harlan SM, Heinz-Taheny KM, Sullivan JM, et al. Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models. *J Am Soc*

- Nephrol.* 2018;29(2):477-491.
12. Rosenthal T, Younis F, Alter A. Combating Combination of Hypertension and Diabetes in Different Rat Models. *Pharmaceuticals.* 2010;3(4):916-939.
 13. Tang M, Wei X, Wan X, Ding Z, Ding Y, Liu J. The role and relationship with efflux pump of biofilm formation in *Klebsiella pneumoniae*. *Microb Pathog.* 2020;147:104244.
 14. Ishii Y, Ohta T, Sasase T, et al. Pathophysiological analysis of female Spontaneously Diabetic Torii fatty rats. *Exp Anim.* 2010;59(1):73-84.
 15. Kemmochi Y, Fukui K, Maki M, et al. Metabolic Disorders and Diabetic Complications in Spontaneously Diabetic Torii Lepr (fa) Rat: A New Obese Type 2 Diabetic Model. *J Diabetes Res.* 2013;2013:948257.
 16. Ohta T, Katsuda Y, Miyajima K, et al. Gender differences in metabolic disorders and related diseases in Spontaneously Diabetic Torii-Lepr(fa) rats. *J Diabetes Res.* 2014;2014:841957.
 17. Katsuda Y, Sasase T, Tadaki H, et al. Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin. *Exp Anim.* 2015;64(2):161-169.
 18. Toriniwa Y, Saito T, Miyajima K, et al. Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model. *J Vet Med Sci.* 2018;80(6):878-885.
 19. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clin J Am Soc Nephrol.* 2017;12(12):2032-2045.
 20. Bayorh MA, Mann G, Walton M, Eatman D. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats. *Clin Exp Hypertens.* 2006;28(2):121-132.
 21. Buss SJ, Backs J, Kreusser MM, et al. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats. *Endocrinology.* 2006;147(5):2526-2534.
 22. Cohen MP, Lautenslager GT, Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. *Metabolism.* 2001;50(12):1435-1440.
 23. Gartner K. Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice (c57bl/6j db/db and c57bl/ksj db/db). *Diabetologia.* 1978;15(1):59-63.
 24. Charytan DM, Forman JP. You are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathy. *Kidney Int.* 2012;82(3):257-259.
 25. Katsuda Y, Kemmochi Y, Maki M, et al. Effects of unilateral nephrectomy on renal function in male Spontaneously Diabetic Torii fatty rats: a novel obese type 2 diabetic model. *J Diabetes Res.* 2014;2014:363126.
 26. O'Sullivan J, Finnie SL, Teenan O, et al. Refining the Mouse Subtotal Nephrectomy in Male 129S2/SV Mice for Consistent Modeling of Progressive Kidney Disease With Renal Inflammation and Cardiac Dysfunction. *Front Physiol.* 2019;10:1365.
 27. Racanicchi IA, Oliveira AB, Barbieri RL, Delle H, Duarte Ida S, Leme PL. Experimental models of renal dysfunction in female rats. Functional and histological aspects after unilateral nephrectomy or ligation of right renal vein with kidney preservation. *Acta Cir Bras.* 2015;30(12):824-830.

28. Heyman SN, Khamaisi M, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. *American journal of nephrology*. 2008;28(6):998-1006.
29. Heyman SN, Khamaisi M, Zorbavel D, Rosen S, Abassi Z. Role of Hypoxia in Renal Failure Caused by Nephrotoxins and Hypertonic Solutions. *Seminars in nephrology*. 2019;39(6):530-542.
30. Heyman SN, Gorelik Y, Zorbavel D, et al. Near-drowning: new perspectives for human hypoxic acute kidney injury. *Nephrol Dial Transplant*. 2020;35(2):206-212.
31. Bobulescu IA. Renal lipid metabolism and lipotoxicity. *Current opinion in nephrology and hypertension*. 2010;19(4):393-402.
32. Afshinnia F, Nair V, Lin J, et al. Increased lipogenesis and impaired beta-oxidation predict type 2 diabetic kidney disease progression in American Indians. *JCI insight*. 2019;4(21).
33. Katsuda Y, Kemmochi Y, Maki M, et al. Physiological changes induced by salt intake in female Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rat, a novel obese type 2 diabetic model. *Animal science journal = Nihon chikusan Gakkaiho*. 2014;85(5):588-594.
34. Saavedra JM. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. *Clinical science*. 2012;123(10):567-590.
35. Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. *American journal of hypertension*. 2015;28(3):289-299.
36. Baylis C, Corman B. The aging kidney: insights from experimental studies. *J Am Soc Nephrol*. 1998;9(4):699-709.
37. Noshahr ZS, Salmani H, Khajavi Rad A, Sahebkar A. Animal Models of Diabetes-Associated Renal Injury. *J Diabetes Res*. 2020;2020:9416419.
38. Lee M, Sorn SR, Lee Y, Kang I. Salt Induces Adipogenesis/Lipogenesis and Inflammatory Adipocytokines Secretion in Adipocytes. *International journal of molecular sciences*. 2019;20(1).
39. Soler MJ, Riera M, Batlle D. New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy. *Exp Diabetes Res*. 2012;2012:616313.
40. Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. *Hypertension research : official journal of the Japanese Society of Hypertension*. 2019;42(6):892-902.
41. Nishiyama A, Yoshizumi M, Rahman M, et al. Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. *Kidney Int*. 2004;65(3):972-981.
42. Hinojosa-Laborde C, Jespersen B, Shade R. Physiology Lab Demonstration: Glomerular Filtration Rate in a Rat. *J Vis Exp*. 2015(101):e52425.
43. Sano R, Ishii Y, Yamanaka M, et al. Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model. *Physiol Res*. 2021;70(1):45-54.
44. Ellery SJ, Cai X, Walker DD, Dickinson H, Kett MM. Transcutaneous measurement of glomerular filtration rate in small rodents: through the skin for the win? *Nephrology (Carlton)*.

2015;20(3):117-123.




Figure 1






Figure 2


(a) Histology




(b) Interstitial fibrosis



(c) Glomerular hypertrophy



(d) Mesangial hyperplasia



(e) Infiltration, inflammatory cell




Figure 3




Figure 4




Figure 5